Oncology research company Champions Oncology Inc (NASDAQ: CSBR) announced on Wednesday that it has enhanced its clinical bioanalytical services portfolio by integrating Cytek Aurora flow cytometers.

With the addition of Cytek Aurora instruments, Champions' capabilities are strengthened in spectral and conventional flow cytometry to enable more complex spectral analysis to better serve its biopharma clients.

The company has also appointed Troy Tremaine, MBA, as head of Bioanalytical Commercial Strategy. Tremaine, a veteran in commercial leadership within the preclinical and bioanalytical sectors, will drive the commercial strategy for this expanding business segment.

Champions Oncology provides comprehensive oncology R&D solutions, leveraging the world's largest annotated bank of patient-derived xenograft and hematological malignancy models. Its proprietary in vivo and ex vivo platforms, coupled with advanced bioanalytical tools and data analytics, support the discovery and development of oncology drugs globally.